Biotech Values

[acgood]

The advantages I can think of off the top of my head are:

1) no sharps container or handling of an exposed needle required

2) perhaps the injection is a bit easier (I notice Copaxone for example has a FIFTY page PDF guide to giving yourself the sub-cutaneous injection


--
Unrelated question-
When Teva wants to offer a new delivery option for Copaxone (ie, the autoject2 is now available to use with the prefilled syringes), what sort of regulatory filing process is required? ie, if Copaxone was another Teva-Antares partner product, what regulatory path would it take? Thanks.